# Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation

> **NCT07561554** · PHASE1 · RECRUITING · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 159 (estimated)

## Conditions studied

- Solid Tumors (Phase 1)

## Interventions

- **DRUG:** HSK42360-Na

## Key facts

- **NCT ID:** NCT07561554
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-06
- **Primary completion:** 2028-12-02
- **Final completion:** 2028-12-02
- **Target enrollment:** 159 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07561554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07561554, "Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07561554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*